Genotypes of single nucleotide polymorphisms are subject to misclassification. If ignored, such misclassification can seriously distort the estimated genotype effects on the disease or outcome of interest. Validation data (gold standard or replicated surrogates) are required to assess the degree of misclassification and make adjustments. In practice, gold standard measurements may be unavailable or impractical. Collecting replicated surrogates is a reasonable option for validation data. In most practical applications, collecting replicated surrogates on all study subjects is not feasible; however, obtaining replicated surrogates on a subsample of the study population may be quite feasible. Generating duplicate data for a subsample of the study population is now common practice among genotyping laboratories. The authors propose a Bayesian method that can adjust for genotype misclassification using partial validation data. Simulation results show that the proposed method substantially reduces misclassification bias from the estimated genotype-disease association and provides appropriate uncertainty assessment, as well as improves other desirable properties of the estimated effects. The authors also provide an example showing the application of the proposed method to study data relating non-Hodgkin lymphoma to a single nucleotide polymorphism in the aryl hydrocarbon receptor gene. bias (epidemiology); genotype; misclassification; polymorphism, single nucleotide Abbreviations: AHR, aryl hydrocarbon receptor; SNP, single nucleotide polymorphism.
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As in most epidemiologic studies, misclassification/ measurement error is almost unavoidable in genetic association studies, since genotype classification, though highly accurate, is not always 100% accurate (1, 2) . If ignored, misclassification in genotype can lead to erroneous inference about the relation between the underlying disease and the susceptibility gene of interest (1, (3) (4) (5) (6) . For a binary risk factor, the presence of nondifferential misclassification biases the actual disease-exposure association toward the null value (5, 7) . When genotypes are dichotomized (in dominant and recessive genetic models), nondifferential misclassification of genotypes reduces the statistical power of a study to detect the genetic association or, equivalently, increases the sample size required to maintain a prespecified statistical power and significance level (6, 8) . The misclassification impact may become substantial if the risk factor prevalence is small-for example, less than 15% (1) . A genotype prevalence of 15% corresponds to a disease allele frequency of approximately 7.5% in dominant genetic models and 38% in recessive and codominant models (9) . Thus, the frequency of the disease allele or minor allele of a genetic marker does not need to be very low for the genotype misclassification to qualitatively influence the estimate of the genotype-disease association.
Increasing the sample size will decrease the standard errors of the estimated effects but will not remove the bias. Furthermore, increasing the sample size can be more harmful when the misclassification is differential and/or the risk factor is polytomous. In such cases, bias due to misclassification can sway the findings either toward or away from the null (5). When bias points away from the null, increasing the sample size can increase the number of spurious findings at a fixed significance level.
It is desirable to have methods for mitigating the adverse effects of genotype misclassification. Additional data for validating the sensitivity and specificity of the called genotype are needed to adjust for misclassification. In most cases, such validation data are available either as 1) a gold standard assessment, along with the usual (imperfect) method of genotyping in a subsample of the study population (10), or 2) 2 or more replicates of the imperfect assessment (replicated surrogates) of genotype (11) . In most practical applications, replicated surrogates may be generated for only a subset of the study subjects. In this article, we propose a Bayesian framework for a logistic regression model that adjusts for genotype misclassification when validation data are available for a subset of the study subjects.
Most approaches found in the literature deal with adjusting the odds ratio in a 232 table. The regression approach is more general, as confounders can be readily accommodated. Kosinski and Flanders (12) presented a maximum likelihood approach implemented via the expectation-maximization algorithm to adjusting for misclassification in a dichotomous exposure while estimating the disease-exposure relation through a logistic regression model. Though their approach is flexible in incorporating both nondifferential and differential misclassification and accommodating both continuous and categorical covariates, it is most applicable when the replicated surrogates of the unobserved exposure are available for the entire study population. Although the maximum likelihood-based methods and the proposed Bayesian framework with noninformative priors should provide similar results (13, 14) , the implementation of likelihood-based approaches becomes difficult when validation data are available for only a subset of the study population. Additional efforts are required to estimate the standard errors of the estimates when the maximum likelihood-based approach is implemented via the expectation-maximization algorithm (5) . Finally, the maximum likelihood-based approaches fail to converge in situations that involve the combination of rare exposure, relatively high sensitivity, and small validation sample size (15) . Bayesian estimation, in contrast, can be implemented in such situations (15, 16) because of regularization of the parameter estimate by the information provided by the prior distribution about the parameter of interest.
In this article, we propose a Bayesian method that can accommodate partial validation data in studying diseasegenotype relations through a logistic regression model in the presence of genotype misclassification. Simulation is used to investigate the impact of misclassification in lowallele-frequency situations (analogous to low exposure prevalence), relevant to genetic association studies. The results show that our proposed method not only mitigates the bias from the genotype misclassification but also provides appropriate uncertainty assessment and improves many other desirable properties of the estimates. In addition, our proposed approach covers the special case in which validation data are available for all subjects. In this special case, our proposed method is similar to that proposed by Ren and Stone (17) .
MATERIALS AND METHODS
The Bayesian adjustment method for exposure measurement error/misclassification is based on the conditional independence model (18) . In this article, we consider partial validation data in terms of replicated surrogates. However, gold standard validation data are also straightforward to accommodate. Let Y be the response and X be the unobserved true exposure. Suppose, in the validation sample, the 2 surrogate assessments of the unobserved true exposure are denoted by X 1 and X 2 . Then, under exposure misclassification, the joint distribution of all of the relevant variables can be formulated as
where u R ; u M ; and u E are the parameter vectors for the response (R), the measurement (M), and the exposure (E) models, respectively. The first term on the right-hand side of equation 1, known as the outcome model, describes the relation between the response Y and the true exposure X. The second term is known as the measurement model, describing how the surrogates X 1 and X 2 arise from X, with the response Y possibly influencing the process. Under nondifferential misclassification,
That is, conditional on X, the joint distribution of X 1 and X 2 does not depend on Y. Finally, the third term is referred to as the exposure model. In this article, we consider a model in which the disease status is related to a dichotomous risk factor X. Such a situation is relevant to dominant and recessive models of genetic association studies.
is the known disease status of the ith (i ¼ 1, 2, . . ., n) study subject. Let X 1i denote the first imperfectly assessed exposure status of the ith study subject. Suppose validation data are available on n v ðn v nÞ study subjects and X 2i is the second imperfectly assessed exposure status for the ith subject in the validation sample. Then the posterior density of the unobserved quantities ðX; u R ; u M ; u E Þ, given the observed quantities (Y, X 1 , X 2 ), is obtained as
where u ¼ ðu R ; u M ; u E Þ, I½n À n v is the index set corresponding to study subjects not in the validation sample and I½n v is the index set corresponding to study subjects in the validation sample. In equation 3, pðuÞ is the joint prior density of u. Note that prior independence of the model parameters is assumed.
In the case of a logistic regression model with a dichotomous exposure, the outcome and exposure models, respectively, are
and
Thus, u R ¼ ðb 0 ; b 1 Þ and u E ¼ p, where p is the prevalence of the true exposure in the study population. Under nondifferential misclassification, the measurement model for the original sample becomes
Under the assumption of conditional independence of the 2 imperfect assessments, along with the assumption of nondifferential misclassification, the measurement model for the validation sample becomes
In equations 6 and 7,
Thus, p 1 and q 1 are the sensitivity and specificity, respectively, of the first imperfect assessment and p 2 and q 2 are the sensitivity and specificity, respectively, of the second imperfect assessment. Note that the conditional independence assumption of the replicated surrogates is tenable when they are true replicates. Otherwise, the Bayesian approach can easily accommodate the dependence among the surrogate assessments.
Under replicated surrogates on a subsample of the study subjects, the joint posterior distribution of the unobservable quantities is obtained as
Although in this article we attempt to incorporate the genotype call itself to adjust for misclassification, it is possible to incorporate the genotype call probabilities in the measurement model to more appropriately acknowledge uncertainty. In such a case, the measurement models defined in equations 6 and 7 need to be multiplied by the corresponding genotype call probabilities. Further effort is needed, however, to work out the mathematical details and the computation via a Markov chain Monte Carlo algorithm.
For Bayesian inference of the parameters in the joint posterior distribution defined in equation 8, we need to specify prior distributions for the components of u. For b 0 and b 1 , we consider diffuse proper priors. The reason for choosing diffuse priors is that in the absence of any plausible prior information, it is reasonable to allow the data to take the prime role in drawing inferences about the regression parameters. Priors for p 1 , q 1 and p 2 , q 2 are chosen on the basis of subject area perspective. Since genotype assay techniques usually have very high sensitivity and specificity, we choose very strong informative priors for these parameters. Finally, for p, a diffuse prior is assumed to express the lack of knowledge about the true exposure prevalence.
Given the joint posterior distribution in equation 8, it is straightforward to derive the posterior conditionals for the unobserved quantities given the observed quantities. The Bayesian inference can then be carried out based on the posterior conditionals by applying appropriate Markov chain Monte Carlo algorithms. The posterior conditionals and the implementation of the Bayesian adjustment method are provided in the Appendix.
RESULTS

Results of the simulation studies
We conduct systematic simulation studies to investigate the impact of genotype misclassification and the performance of the Bayesian adjustment method while modeling the genotype-disease association via a logistic regression model. We consider a dominant genetic model, where minor-allele homozygotes and heterozygotes are grouped into 1 ''exposure'' category. Genotype-disease associations (expressed in terms of log odds ratio ðb 1 Þ or odds ratio) of 3 different strengths are considered for the simulation-
, and 3) b 1 ¼ 0:75 (odds ratio ¼ 2.12). Under each odds ratio, 2 sensitivity-specificity pairs [(0.95, 0.95) and (0.98, 0.98)], corresponding to misclassification rates of 5% and 2%, respectively, are considered. Under each combination of odds ratio and sensitivity-specificity pair, 4 different minor allele frequencies (2.5%, 5%, 7.5%, and 10%) corresponding to a dominant model exposure prevalence of approximately 5%, 10%, 14%, and 19% are considered. In each case, 3 different sample sizes, n ¼ 200, 500, and 1,000, are investigated. For validation data, we generate 2 replicates of the imperfect (surrogate) assessments in a randomly selected subset of size 200 (n v ¼ 200) of the study population. Finally, we assume that the misclassification is nondifferential with respect to disease status. Under the proposed Bayesian adjustment method, the hyperparameters for the priors are chosen to reflect the principles in choosing the priors described above in Materials and Methods. For b 0 and b 1 , we consider normal priors with mean 0 and variance 10. For p 1 , q 1 , p 2 , and q 2 , we choose very informative b priors centered at 0.95 and giving a probability of 0.85 that p 1 , q 1 , p 2 , and q 2 lie within the interval (0.9, 1). This leads to a b prior equivalent to b(10, 0.5). Gustafson et al. (16) considered such a prior for sensitivity and specificity when there is strong partial knowledge of these parameters but no validation data are available. Finally, for the exposure prevalence p, a diffuse b prior, b(1, 1), is assumed.
The proposed adjustment method is implemented in the R programming language (19) . (The R code is available from the authors upon request.) Under each simulation setting, we generate 300 data sets and estimate the log odds ratio by ignoring the misclassification (naive estimates) and by the proposed adjustment method (adjusted estimates) from each data set. The naive estimates are obtained by fitting a logistic regression of the response Y on the first surrogate genotype assessment, X 1 , done for the entire study population. Therefore, the naive estimates ignore the validation data, since they are not adjusted for misclassification. The results are summarized over the 300 simulated data sets. We compare the results with the benchmark estimate obtained by regressing the response on the true genotype. Results derived under the case of no genetic association (null case) are presented in Table 1 , and those derived under the nonnull case with b 1 ¼ 0:75 are presented in Table 2 . The results for the other nonnull case (b 1 ¼ 0:50) are presented in the Appendix Table. We report the mean b 1 estimates and their standard deviations, the coverage probability of the 95% credible intervals, and the empirical power to detect an association. The empirical power is computed by dividing the number of credible intervals (out of 300) not including the null value 0 by the number of data sets. For the null case, it gives the type I error, and in the 2 nonnull cases it gives the study power.
Results show that in the null case (b 1 ¼ 0), misclassification does not have any adverse impact on the estimated genotype effect. This is in agreement with the results in linear regression, where it can be shown that the presence of measurement error/misclassification does not affect the disease-exposure association. However, as expected, the adjustment for misclassification is found to produce increased variability of the estimated association. Both the naive estimate and the adjusted estimate are found to provide credible intervals that have coverage probability close to the nominal coverage probability of 0.95. Finally, both of the estimates are found to perform very similarly to the corresponding benchmark estimates with respect to type I error.
In the 2 nonnull cases, results (Table 2 and Appendix Table) reveal that the naive estimates are heavily biased downward with variability lower than that of the corresponding benchmark estimates. The magnitude of bias increases as the exposure prevalence (or equivalently, the disease allele frequency) decreases. The far-more-deleterious impact of misclassification for low exposure prevalence can be explained by the fact that there are very few exposed subjects but a very large number of unexposed subjects in the study population. Hence, on average, far more unexposed subjects will be misclassified as exposed subjects (as compared with exposed subjects' being misclassified as unexposed subjects) in both the case group and the control group, thus making the 2 groups more balanced in terms of risk factor prevalence and leading to attenuation of the estimates. The amount of bias, however, is less pronounced, especially in the case of a 2% misclassification rate, where exposure prevalence exceeds 15% (results omitted).
On the other hand, as observed from the simulation results, the Bayesian adjustment method provides unbiased estimates of the genotype-disease association (log odds ratio), with increased uncertainty (reflected by larger standard deviations of the estimates) in all of the simulation settings considered. This extra variability correctly reflects the loss of information associated with misclassification. The artificially low variability of the naive estimates is neither desirable nor justified, because it is due to ignoring information loss in classifying the true exposure. In addition, the coverage probabilities of the 95% credible interval based on the adjusted estimates are almost identical to the nominal coverage probability of 0.95, whereas the 95% credible intervals based on naive estimates suffer from severe undercoverage. More damaging is the fact that as the sample size grows, the coverage probability decreases. That is, as the sample size increases, the naive analysis provides an incorrect association estimate with higher precision. Finally, as is observed from the simulation results, the Bayesian adjustment results in an improvement in statistical power to detect the genotype effects over the naive estimates. We expect similar gains in statistical power in genetic association studies, despite fewer validation samples, since strong priors for the sensitivity and specificity are generally appropriate.
To assess the sensitivity of our model to misspecification of the hyperparameters, we conducted a small simulation with b 1 ¼ 0.75, n ¼ 500, 5% exposure prevalence, true sensitivity and specificity of 0.80, and 300 simulated data sets. Application of our method with a b(10, 0.5) prior for the sensitivity and specificity (i.e., 85% chance that the sensitivity and specificity are above 0.9) yielded an averagê b 1 of 0.717 (standard deviation, 0.989). This result indicates that even though the true sensitivity and specificity are quite far from the center of the prior distribution, there is only a small bias in the estimated log odds ratio. Thus, the proposed method was found to be reasonably robust against moderate misspecification of the hyperparameters.
Finally, in the unlikely case of no misclassification, our proposed method would lead to inflated standard errors ofb 1 because it allows some variability through the priors for sensitivity and specificity. Results of a small simulation study (the first simulation in Table 2 is repeated, where data are generated with no misclassification) show an increase in the variability ofb 1 after adjustment (a standard deviation of 0.624 for the adjusted estimate against 0.604 for the unadjusted estimate). Even though the prior distributions for sensitivity and specificity allow 5% misclassification on average and an approximately 15% chance that the misclassification rate is above 5%, the increase in the variability of the b 1 estimate is reasonably small. To illustrate an application of the Bayesian adjustment method in an experimental situation where partial validation data are available, we analyze data relating the risk of nonHodgkin lymphoma to single nucleotide polymorphism (SNP) genotype variation in the aryl hydrocarbon receptor (AHR) gene. Variation in the AHR gene has been hypothesized to be a risk factor for non-Hodgkin lymphoma (20) . This work addressed the effects of organochlorines, genetic variation in the AHR gene, and gene-organochlorine interactions on the risk of non-Hodgkin lymphoma, controlling for other sociodemographic factors. The population-based case-control study was conducted in British Columbia, Canada. Details on the study design, including the assessment of genetic and environmental factors, are available in the article by Spinelli et al. (21) . For the genetic association analysis, 775 cases and 768 controls were available. Here we consider 1 SNP, IVS1-3946 G/A, as an analysis example. Genotyping was performed with a TaqMan allelic discrimination assay, designed using the Assays-by-Design service (Applied Biosystems, Inc., Foster City, California). For this SNP, the 2 alleles G (minor allele) and A (major allele) give rise to genotype categories GG, GA, and AA. For our analysis, we consider a recessive model. That is, heterozygotes (GA) and major-allele homozygotes (AA) are put into the ''unexposed'' group. For the assumed genetic model, the prevalence of the observed exposure is found to be 12% in the study population.
Finally, for this analysis, samples are classified as either ''high'' or ''low'' depending on the amount of DNA available in the collected blood or saliva samples. A sample containing an amount of DNA less than 10 ng/lL is considered to provide a lower-confidence genotype measurement than a sample with a high amount of DNA (!10 ng/lL). Because the accuracy of the genotype assessment can be affected by the amount of DNA, we assume that high and low samples have different sensitivities and specificities. From equation 7, it is clear that different sensitivities and specificities of the replicated assessments can be accommodated in the Bayesian framework.
In this analysis, out of 1,543 study subjects, 120 (81 cases and 39 controls) had 2 surrogate genotype assessments. That is, we had a validation sample of size 120 (n v ¼ 120). Information on the validation sample is presented in Table 3 .
Out of 120 study subjects with 2 surrogate assessments, the first and second assessments did not match for 5 subjects, which is an indication of misclassification in the surrogate assessments. Out of 1,423 subjects with single assessments, 965 had high samples and 458 had low samples. In the validation sample, 16 had high samples on both assessments, 84 had low samples on the first assessment and high samples on the second assessment, 10 had high samples on the first assessment and low samples on the second assessment, and 10 had low samples on both assessments. The data were analyzed using a logistic regression model to assess the genotype effects on the risk of non-Hodgkin lymphoma. Results are presented in Table 4 . For the Bayesian adjustment method, hyperparameters used for different priors are the same as those considered in the simulation studies presented in the previous section.
After adjustment for misclassification under the proposed Bayesian adjustment method, the estimated log odds ratio Àb 1 Á for being minor-allele homozygous as opposed to heterozygous or major-allele homozygous was found to be 0.245, as opposed to 0.190 obtained under the naive logistic regression model. As expected, the posterior standard deviation ofb 1 increased slightly (0.173 for the adjusted estimate vs. 0.150 for the naive estimate). Accordingly, the 95% credible interval for the odds ratio based on the adjusted estimate appeared to be wider than that based on the naive estimate. However, the wider credible interval under the adjusted estimate was due to the much higher upper limit of the interval. The lower limits of both credible intervals were very close to each other. Although, in this particular example, we did not observe a qualitative difference in terms of the statistical significance of the odds ratio estimate, the point and interval estimates under the proposed adjustment method were quantitatively different from those obtained under the naive logistic regression model. Finally, the estimated sensitivities of high and low measurements were found to be 0.96 and 0.94, respectively, and the specificities were found to be 0.99 and 0.98, respectively. 
DISCUSSION
Since genotypes are usually classified with a higher degree of accuracy than environmental exposures, it is generally believed that the small amount of misclassification in genotyping may not be problematic. However, for some SNPs, the bias in the odds ratio estimate can be substantial and still needs to be addressed, because 1) misclassification in categorical covariates causes a larger bias in the odds ratio estimate than measurement error in continuous covariates (5) and 2) even a minor degree of misclassification can lead to a large bias in the odds ratio estimate if exposure prevalence is low ( 15%) (1) . Moreover, the direction of the effects is unpredictable when the misclassification is differential and/or when more than 1 covariate is included in the model with 1 or more having misclassification/measurement error (5, 22) . In gene-environment interaction studies, if both the genetic and the environmental factors are measured with error, the combination of both errors can lead to a very substantial distortion of the gene-environment interaction effects on the disease outcome, with qualitatively different interpretations.
In view of the multifarious damaging effects of covariate measurement errors/misclassification, the most reasonable option is to adjust for them at the analysis stage. Simulation results demonstrate that, utilizing only the partial validation data, the proposed adjustment method provides adequate correction for bias in the estimated genotype effects on the disease risk with proper uncertainty assessment. Furthermore, the adjustment method provides estimates that have many desirable properties, such as producing credible intervals with appropriate coverage probability and providing statistical power that is closer to the true power as compared with that of the naive estimates.
A potential limitation of our proposed method is that when gold standard measurements are not available, there is an implicit assumption that replicated surrogates carry information about sensitivity and specificity. This assumption may not be satisfied in some cases; for example, some SNPs may behave poorly because they are in regions that are difficult to genotype. For such SNPs, replicates may be concordant but incorrect and thus may lead to overestimation of true sensitivity and specificity. In this case, our method will not be able to adjust for the misclassification, and the results would be similar to those obtained by ignoring misclassification.
Our proposed Bayesian method provides a general framework with which to adjust for misclassification by incorporating partial validation data in a unified theory. We demonstrate how the Bayesian framework can be modified to accommodate replicated surrogates in a subsample of the study population. Because of its flexibility in utilizing validation data in a subsample of the study subjects, this method can have practical implications in studies of geneenvironment associations, studies of gene-environment interactions, and many other epidemiologic studies where cost and other constraints prohibit collection of replicated data on the entire study population. Furthermore, the Bayesian method can be readily extended to handle measurement errors and/or misclassification in more than 1 covariate (discrete or continuous) in a simple manner. It can also accommodate complicated design scenarios like longitudinal studies, information measured through different instruments (18) , differential misclassification, etc. The Bayesian method is computationally more tractable than the maximum likelihood approach by virtue of its use of Markov chain Monte Carlo computational techniques, and the uncertainty assessments of the estimated effects are automatic (5, 16).
6. The posterior conditional for q 2 is obtained as
7. The posterior conditional for p is obtained as
Thus, the posterior draws of p 1 , q 1 , p 2 , q 2 , and p are easily obtained from their respective b posterior conditionals.
The parameter estimates under the proposed Bayesian adjustment method are obtained by summarizing the Markov chain Monte Carlo (MCMC) draws from the respective posterior conditionals using 10,000 MCMC draws after a burn-in of 5,000 draws. For monitoring the convergence of the MCMC runs of model parameters, MCMC chains generated with 2 widely dispersed starting points are plotted against the time sequence (24) for 5 data sets selected at random under each simulation setting. For the selected data sets, we observe that the 2 chains starting from 2 different points become indistinguishable after a small number (<500) of initial iterations. This confirms that the MCMC chain converges to the underlying posterior distribution quickly. It also demonstrates that at convergence, the MCMC chains are insensitive to the starting values. For all of the model parameters, especially b 1 , we observe reasonable mixing and convergence of the MCMC chains.
(Appendix Table Follows Abbreviations: CP95, coverage probability of the 95% credible interval; SD, standard deviation. a Results are summarized over 300 data sets.
